TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11752031

Group type: EXPERIMENTAL
Intervention: Prednisolone and cytotoxic agents
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide then azathioprine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 38
Study: 10662477

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 640

Group type: COMPARATOR
Intervention: Flunisolide
Number of subjects: 640
Study: 7595873

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural tinnitus coping training (TCT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 43

Group type: COMPARATOR
Intervention: Self-monitoring control group
Number of subjects: 43
Study: 12316339

Group type: EXPERIMENTAL
Intervention: Combined low-dose estrogen and progesterone pills
Number of subjects: 100

Group type: COMPARATOR
Intervention: Different methods of birth control (control group)
Number of subjects: 100
Study: 843794

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipyridamole (alone and in combination with aspirin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0
Study: 29406177

Group type: EXPERIMENTAL
Intervention: Thirst-driven fluid administration (200 ml bolus triggered by participants)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Thirst-driven fluid administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clinician-directed fluid management (1.25 ml kg‐1 h‐1 with 500 ml bolus)
Number of subjects: 16
Study: 27673530

Group type: EXPERIMENTAL
Intervention: Standard information plus access to BRECONDA (intervention)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard online information about breast reconstruction (control)
Number of subjects: 222
Study: 24692626

Group type: EXPERIMENTAL
Intervention: Polylevolactic acid screws
Number of subjects: 168

Group type: COMPARATOR
Intervention: Metallic screws
Number of subjects: 168
Study: 23328379

Group type: EXPERIMENTAL
Intervention: CIK via intravenous drop infusion for more than 6 times (study group)
Number of subjects: 95

Group type: COMPARATOR
Intervention: TACE combined with RFA (control group)
Number of subjects: 95
Study: 20193998

Group type: EXPERIMENTAL
Intervention: Patient self-reported regular exercise
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Patient self-reported efforts to lose weight (eating less)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Physician perception of patient exercise
Number of subjects: 274

Group type: COMPARATOR
Intervention: Physician perception of patient weight loss efforts
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Kappa score for patient self-reported exercise
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Kappa score for patient self-reported weight loss efforts
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Obese patients reporting weight loss efforts or regular exercise
Number of subjects: 274

Group type: COMPARATOR
Intervention: Physician perception of obese patients' activities
Number of subjects: 274
Study: 18611068

Group type: EXPERIMENTAL
Intervention: Anti-adhesion molecule therapy; specific agents not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-TNF therapy (infliximab, adalimumab)
Number of subjects: 0
Study: 16025962

Group type: EXPERIMENTAL
Intervention: Puerarin injection (PI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fructose‐1,6‐disphosphate (FDP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 100
Study: 11432713

Group type: EXPERIMENTAL
Intervention: Vitamins/mineral and garlic preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 9683123

Group type: EXPERIMENTAL
Intervention: Electrocautery (n = 42)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Scalpel (n = 38)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Jackson‐Pratt drains
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Lower estimated blood loss
Number of subjects: 74
Study: 7811509

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% + epinephrine 1:200,000 infiltration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline infiltration
Number of subjects: 50
Study: 2907349

Group type: EXPERIMENTAL
Intervention: bopindolol, 1 mg once daily for 1 week
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: atenolol, 50 mg once daily for 1 week
Number of subjects: 10

Group type: COMPARATOR
Intervention: adrenaline infusion (20 ng/kg per min)
Number of subjects: 10
Study: 1929842

Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg per rectum, four times per day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide (500 mg per rectum, four times per day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (no radical scavengers, only analgesic regimen)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Allopurinol or Dimethyl sulfoxide
Number of subjects: 66
Study: 324238

Group type: EXPERIMENTAL
Intervention: G 31.406
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Orphenadrine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 30767563

Group type: EXPERIMENTAL
Intervention: Prophylactic procedure for inguinal hernia (IH) after RARP
Number of subjects: 148

Group type: COMPARATOR
Intervention: No prophylactic procedure (control)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Prophylactic procedure for IH
Number of subjects: 148
Study: 28032413

Group type: EXPERIMENTAL
Intervention: Dynamic animations
Number of subjects: 167

Group type: COMPARATOR
Intervention: Static images
Number of subjects: 167
Study: 26039019

Group type: EXPERIMENTAL
Intervention: Regular physical activity (PA)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Regular physical activity (PA) and vitamin C supplementation (C)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (healthy individuals without MS)
Number of subjects: 62
Study: 22763493

Group type: EXPERIMENTAL
Intervention: Implementation strategy (multifaceted training programme)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Implementation strategy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 21375731

Group type: EXPERIMENTAL
Intervention: Cooperation mechanism between local CDCs and university hospitals (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care without cooperation mechanism (control group)
Number of subjects: 0
Study: 21141016

Group type: EXPERIMENTAL
Intervention: Manual Small-Incision Cataract Surgery (MSICS)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional Extracapsular Cataract Extraction with PCIOL (ECCE with PCIOL)
Number of subjects: 88
Study: 17194863

Group type: EXPERIMENTAL
Intervention: Brief intervention (10-15 minute counseling sessions by a nutritionist)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 255

Group type: COMPARATOR
Intervention: Assessment-only condition
Number of subjects: 255
Study: 15047679

Group type: EXPERIMENTAL
Intervention: 19% fat diet
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 50% fat diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: 30% fat diet (control)
Number of subjects: 11
Study: 11255420

Group type: EXPERIMENTAL
Intervention: Physical activity (walking)
Number of subjects: 39372

Group type: EXPERIMENTAL
Intervention: Walking pace
Number of subjects: 39372

Group type: EXPERIMENTAL
Intervention: Physical activity (general)
Number of subjects: 39372
Study: 9676837

Group type: EXPERIMENTAL
Intervention: Oral 13‐cis‐retinoic acid at a dose of 1 mg/kg
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: 0.5‐4 microM concentrations of 13‐cis‐retinoic acid
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 147
Study: 7740961

Group type: EXPERIMENTAL
Intervention: Timopentina (50 mg/3 times per week for 6 weeks, 4 or 5 cycles during the year)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no timopentina)
Number of subjects: 25
Study: 2691169

Group type: EXPERIMENTAL
Intervention: Experimental dental rinse (15 ml, rinsed for 30 seconds)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional mouthwash
Number of subjects: 0
Study: 5332751

Group type: EXPERIMENTAL
Intervention: Analgesic-sedative combination (Fiorinal-C(1/4))
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Analgesic (APC-C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31899315

Group type: EXPERIMENTAL
Intervention: 5-FU + mBYD
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: mBYD
Number of subjects: 615
Study: 30238401

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 27138893

Group type: EXPERIMENTAL
Intervention: School-based Cognitive Behavioural Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25539586

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil (600 mg every 12 h)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Ceftriaxone (2 g every 24 h)
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 847

Group type: COMPARATOR
Intervention: Ceftaroline fosamil and Ceftriaxone
Number of subjects: 847
Study: 23906491

Group type: EXPERIMENTAL
Intervention: Home-based eccentric training program based on the Alfredson protocol (straight leg and bent knee heel drops and raises)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Home-based eccentric training program based on the Alfredson protocol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (subjects without lower extremity pain)
Number of subjects: 20
Study: 21571593

Group type: EXPERIMENTAL
Intervention: 0.5 mg fingolimod
Number of subjects: 1027

Group type: EXPERIMENTAL
Intervention: 1.25 mg fingolimod
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Interferon beta‐1a to 0.5 mg fingolimod
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Interferon beta‐1a to 1.25 mg fingolimod
Number of subjects: 1027
Study: 19124845

Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine (L-NMMA)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 16716322

Group type: EXPERIMENTAL
Intervention: Day 2 embryo transfer
Number of subjects: 281

Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 281
Study: 15057570

Group type: EXPERIMENTAL
Intervention: Presence of a prosthetic valve (PV)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Infection with Enterococcus faecalis
Number of subjects: 41

Group type: COMPARATOR
Intervention: Age, gender, race, polymicrobial infection, community-acquired infection
Number of subjects: 41
Study: 11890582

Group type: EXPERIMENTAL
Intervention: Home hazard assessment, information on hazard reduction, and installation of safety devices (n = 570)
Number of subjects: 1737

Group type: COMPARATOR
Intervention: No safety devices or information on home hazard reduction (n = 1,167)
Number of subjects: 1737
Study: 9457525

Group type: EXPERIMENTAL
Intervention: Frequent follow-up
Number of subjects: 597

Group type: COMPARATOR
Intervention: Control group with follow-up every 5 years
Number of subjects: 597
Study: 8162725

Group type: EXPERIMENTAL
Intervention: High flow transtracheal oxygen (HFTTO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High flow nasal prongs (HFNP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low flow transtracheal oxygen (LFTTO)
Number of subjects: 10
Study: 17171925

Group type: EXPERIMENTAL
Intervention: High-dose fentanyl (75 microg/kg followed by 0.3 microg/kg/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diazepam-ketamine (0.8 mg/kg D and 2 mg/kg K followed by 0.07 mg/kg/h D and 1 mg/kg/h K)
Number of subjects: 40
Study: 31451920

Group type: EXPERIMENTAL
Intervention: Prediction model for readmission for dehydration after DLI creation
Number of subjects: 25638
Study: 30514262

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg bis in die)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of aspirin and metformin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Aspirin and Metformin
Number of subjects: 160
Study: 27253336

Group type: EXPERIMENTAL
Intervention: Simulated Learning Environments (SLE) - two 3-hour workshops with simulated clinical teaching scenarios and facilitated debrief.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard Education (StEd) - two online learning modules.
Number of subjects: 18
Study: 24022570

Group type: EXPERIMENTAL
Intervention: HighCHO diet (70% carbohydrate, 20% fat, 10% protein)
Number of subjects: 15

Group type: COMPARATOR
Intervention: ModCHO diet (45% carbohydrate, 45% fat, 10% protein)
Number of subjects: 15

Group type: COMPARATOR
Intervention: HighCHO diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: LowCHO diet (70% fat, 20% carbohydrate, 10% protein)
Number of subjects: 15
Study: 23147172

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Hypertensive participants
Number of subjects: 1478
Study: 20922480

Group type: EXPERIMENTAL
Intervention: Workload score based on the number of drugs involved, type of literature search performed, and judgmental categorization.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Type of literature search performed.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Categorization of queries as judgmental or not.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Number of drugs involved.
Number of subjects: 20
Study: 19076571

Group type: EXPERIMENTAL
Intervention: Lateral decubitus, knee-chest position with a 45 degree head up tilt (group II, n = 90)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard lateral decubitus, knee-chest position (group I, n = 90)
Number of subjects: 180
Study: 16398601

Group type: EXPERIMENTAL
Intervention: T'ai Chi (TC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (EX)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 12433892

Group type: EXPERIMENTAL
Intervention: Spontaneous hyperventilation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (20 age matched controls)
Number of subjects: 51
Study: 10029561

Group type: EXPERIMENTAL
Intervention: Formoterol, 12 microg once daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Formoterol, 6 microg twice daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Formoterol, 24 microg twice daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Terbutaline, 500 microg four times daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lower doses of formoterol (12 microg once daily or 6 microg twice daily)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All treatments pooled
Number of subjects: 38
Study: 7479225

Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg) and atropine (0.02 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study: 2111697

Group type: EXPERIMENTAL
Intervention: rTPA
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7192511

Group type: EXPERIMENTAL
Intervention: Domperidone, 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atropine, 0.6 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atropine after Domperidone
Number of subjects: 10
Study: 31999753

Group type: EXPERIMENTAL
Intervention: ART during postpartum (PP‐only)
Number of subjects: 4627

Group type: COMPARATOR
Intervention: AP‐only (ART use limited to the antepartum period)
Number of subjects: 4627

Group type: COMPARATOR
Intervention: No ART during postpartum (PP‐only)
Number of subjects: 4627
Study: 31487627

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Alternative treatment
Number of subjects: 74
Study: 27689735

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Baricitinib (4 mg)
Number of subjects: 684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study: 27866177

Group type: EXPERIMENTAL
Intervention: Cranberry juice (4 oz daily for 6 months)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo juice (for 6 months)
Number of subjects: 55
Study: 25518299

Group type: EXPERIMENTAL
Intervention: Subcuticular running 4‐0 Poliglecaprone 25 (Monocryl)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Subcuticular running 4‐0 Polydioxanone (PDS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Subcuticular running 4‐0 Poliglecaprone 25 (Monocryl) and running horizontal mattress 6‐0 Nylon
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Subcuticular running 4‐0 Polydioxanone (PDS) and running horizontal mattress 6‐0 Nylon
Number of subjects: 80

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 80
Study: 22816441

Group type: EXPERIMENTAL
Intervention: 10,600‐nm carbon dioxide laser
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2790‐nm yttrium scandium gallium garnet laser
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of all devices
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 20022264

Group type: EXPERIMENTAL
Intervention: Intravenous treprostinil
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 18536066

Group type: EXPERIMENTAL
Intervention: WSKY capsule added on risperidone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo added on risperidone
Number of subjects: 200
Study: 15572397

Group type: EXPERIMENTAL
Intervention: Retrospective dosimetry using FISH translocations for patients with lower earlier dose estimates (up to about 3 Gy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Retrospective dosimetry using FISH translocations for patients with higher earlier dose estimates (up to about 12 Gy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Repeated chromosomal examinations during the follow-up period
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: First phase of decline in dicentric frequencies
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Second phase of decline in dicentric frequencies
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dicentric levels 10-13 years later
Number of subjects: 10
Study: 14651349

Group type: EXPERIMENTAL
Intervention: 201Tl pelvic SPECT imaging in prostate cancer patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: 201Tl pelvic SPECT imaging in benign prostatic hyperplasia patients
Number of subjects: 25
Study: 10471984

Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg three times daily for 2 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Phenytoin 100 mg three times daily for 2 weeks
Number of subjects: 12
Study: 8560996

Group type: EXPERIMENTAL
Intervention: Minprostin gel (0.5 mg intracervical Gel)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Minprostin tablets (3 mg vaginal tablets)
Number of subjects: 208
Study: 8478315

Group type: EXPERIMENTAL
Intervention: Dirithromycin (two 250 mg tablets, once daily)
Number of subjects: 553

Group type: COMPARATOR
Intervention: Erythromycin (four 250 mg tablets, four times daily)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Dirithromycin
Number of subjects: 553

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Dirithromycin and Erythromycin
Number of subjects: 553
Study: 3563255

Group type: EXPERIMENTAL
Intervention: Theostat 200
Number of subjects: 10

Group type: COMPARATOR
Intervention: Theodur 200
Number of subjects: 10
Study: 29584917

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 43

Group type: COMPARATOR
Intervention: Tobacco withdrawal
Number of subjects: 43
Study: 29254080

Group type: EXPERIMENTAL
Intervention: 20-mg telmisartan (Micardis)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40-mg telmisartan (Micardis)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27117283

Group type: EXPERIMENTAL
Intervention: Real tDCS after rTMS
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Open-label tDCS
Number of subjects: 23

Group type: COMPARATOR
Intervention: Real tDCS
Number of subjects: 23
Study: 24257146

Group type: EXPERIMENTAL
Intervention: Subfascial catheter with continuous levobupivacaine infusion (Group S)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural analgesia with continuous levobupivacaine infusion (Group E)
Number of subjects: 50
Study: 24952282

Group type: EXPERIMENTAL
Intervention: Hip-Hop to Health (HH) intervention delivered by peer educators through EFNEP and SNAP-Ed programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard EFNEP and SNAP-Ed nutrition education curriculum
Number of subjects: 0
Study: 23109696

Group type: EXPERIMENTAL
Intervention: CAP45 (45-Gy RT for 5 weeks with concurrent capecitabine)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: CAPOX50 (50-Gy RT for 5 weeks with concurrent capecitabine and oxaliplatin)
Number of subjects: 598

Group type: COMPARATOR
Intervention: CAP45
Number of subjects: 598

Group type: COMPARATOR
Intervention: CAPOX50
Number of subjects: 598
Study: 19056642

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD) supplemented with virgin olive oil or nuts
Number of subjects: 721

Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 721